Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 9/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.57 |
| ▸ | BACE1 | P56817 | 9/20 | 0.49 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375819 | 0.94 | OPRM1 (0.54) | OPRD1OPRM1BACE1BACE2OPRK1 | |
| SCHEMBL30054207 | 0.93 | BACE1 (0.51) | OPRD1OPRM1BACE1BACE2CTSD | |
| SCHEMBL29674783 | 0.90 | OPRM1 (0.53) | OPRD1OPRM1BACE1BACE2OPRK1 | |
| SCHEMBL18047563 | 0.89 | BACE1 (0.56) | OPRD1OPRM1BACE1BACE2CTSD | |
| SCHEMBL29804647 | 0.89 | BACE1 (0.51) | OPRD1OPRM1BACE1BACE2OPRK1 | |
| SCHEMBL29375389 | 0.88 | BACE1 (0.56) | OPRD1OPRM1BACE1BACE2CTSD | |
| SCHEMBL29375740 | 0.88 | BACE1 (0.56) | OPRD1OPRM1BACE1BACE2CTSD | |
| SCHEMBL29436286 | 0.87 | OPRM1 (0.55) | OPRD1OPRM1OPRK1 | |
| SCHEMBL31215075 | 0.87 | OPRD1 (0.64) | OPRD1OPRM1OPRK1 | |
| SCHEMBL31257069 | 0.85 | OPRD1 (0.57) | OPRD1OPRM1BACE1OPRK1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518794-B2 | Synthesis method for liraglutide with low racemate impurity | Shenzhen JYMed Technology Co., Ltd. (CN) | 2022-12-06 | — | — | US | claimed |
| EP-3864032-B1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | FRESENIUS KABI IPSUM S R L (IT) | 2022-11-30 | — | — | EP | claimed |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-07-26 | — | — | US | claimed |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-02-10 | — | — | US | claimed |
| US-12115225-B2 | GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof | ASTRAZENECA AB (SE) | 2024-10-15 | — | — | US | disclosed |
| US-11518794-B2 | Synthesis method for liraglutide with low racemate impurity | Shenzhen JYMed Technology Co., Ltd. (CN) | 2022-12-06 | — | — | US | disclosed |
| EP-3864032-B1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | FRESENIUS KABI IPSUM S R L (IT) | 2022-11-30 | — | — | EP | disclosed |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-07-26 | — | — | US | disclosed |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | GLP1R, IAPP, VIP | OPRD1 3405/4885OPRM1 4009/4885BACE1 569/4885 |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | GLP1R, IAPP, VIP | OPRD1 3405/4885OPRM1 4009/4885BACE1 569/4885 |
| US-12115225-B2 | GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof | GLP1R, GIPR, GRPR | OPRD1 1624/4885OPRM1 695/4885BACE1 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.